Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine MR vs IR GI Tolerability and PK in Healthy Women
NCT02112903Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Apr 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Lundbeck. Primary endpoints: Gastro-intestinal tolerability (nausea), Gastro-intestinal tolerability (abdominal pain) and 5 more. Started Apr 2014; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02112903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112903.